IL2 and breast carcinoma: The expression product was given the name “melittin‐MIL‐2.” Our prior investigations have shown that the novel cytokine fusion protein “melittin‐MIL‐2” can exert more intense immune effects than IL‐2, inhibit the proliferation of ovarian cancer cell SKOV3 in vitro, and hamper the development of ovarian cancer, liver cancer, and breast cancer metastasis in vivo [12, 13].